USANA Health Sciences Inc. (NYSE:USNA) Director Myron W. Wentz sold 10,000 shares of USANA Health Sciences stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $123.99, for a total transaction of $1,239,900.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

USANA Health Sciences Inc. (NYSE:USNA) opened at 126.85 on Monday. USANA Health Sciences Inc. has a 12 month low of $92.00 and a 12 month high of $150.00. The firm has a market capitalization of $1.59 billion, a PE ratio of 15.73 and a beta of 1.20. The stock has a 50 day moving average of $136.92 and a 200 day moving average of $128.95.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, October 25th. The company reported $2.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.27. The company earned $254.22 million during the quarter, compared to the consensus estimate of $263.37 million. USANA Health Sciences had a net margin of 10.31% and a return on equity of 35.94%. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.92 earnings per share. On average, equities analysts predict that USANA Health Sciences Inc. will post $8.13 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Several brokerages have weighed in on USNA. DA Davidson lifted their price objective on shares of USANA Health Sciences from $135.00 to $150.00 and gave the stock a “neutral” rating in a research note on Thursday, July 28th. Zacks Investment Research upgraded shares of USANA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $158.00 price objective for the company in a research note on Saturday, July 30th.

Institutional investors have recently bought and sold shares of the stock. BlackRock Institutional Trust Company N.A. raised its position in USANA Health Sciences by 15.8% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 163,822 shares of the company’s stock valued at $18,255,000 after buying an additional 22,326 shares during the last quarter. Nordea Investment Management AB raised its position in USANA Health Sciences by 2,844.8% in the third quarter. Nordea Investment Management AB now owns 149,951 shares of the company’s stock valued at $20,746,000 after buying an additional 144,859 shares during the last quarter. BlackRock Fund Advisors raised its position in USANA Health Sciences by 4.5% in the third quarter. BlackRock Fund Advisors now owns 133,939 shares of the company’s stock valued at $18,530,000 after buying an additional 5,798 shares during the last quarter. Teachers Advisors LLC raised its position in USANA Health Sciences by 44.3% in the third quarter. Teachers Advisors LLC now owns 91,587 shares of the company’s stock valued at $12,671,000 after buying an additional 28,115 shares during the last quarter. Finally, Old Mutual Global Investors UK Ltd. raised its position in USANA Health Sciences by 52.8% in the third quarter. Old Mutual Global Investors UK Ltd. now owns 90,316 shares of the company’s stock valued at $12,495,000 after buying an additional 31,211 shares during the last quarter. Institutional investors own 41.55% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. It operates as a direct selling company in approximately two geographic regions: Americas and Europe, and Asia Pacific, which includes approximately three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

5 Day Chart for NYSE:USNA

Receive News & Stock Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related stocks with our FREE daily email newsletter.